Peter O. Hofgaard

1.3k total citations
19 papers, 1.0k citations indexed

About

Peter O. Hofgaard is a scholar working on Immunology, Oncology and Hematology. According to data from OpenAlex, Peter O. Hofgaard has authored 19 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Immunology, 10 papers in Oncology and 5 papers in Hematology. Recurrent topics in Peter O. Hofgaard's work include Immunotherapy and Immune Responses (12 papers), T-cell and B-cell Immunology (10 papers) and Immune Cell Function and Interaction (6 papers). Peter O. Hofgaard is often cited by papers focused on Immunotherapy and Immune Responses (12 papers), T-cell and B-cell Immunology (10 papers) and Immune Cell Function and Interaction (6 papers). Peter O. Hofgaard collaborates with scholars based in Norway, Japan and Switzerland. Peter O. Hofgaard's co-authors include Bjarne Bogen, Hilde Omholt, Alexandre Corthay, Katrin U. Lundin, Egil Røsjø, Guttorm Haraldsen, Zlatko Dembić, Ludvig A. Munthe, Grete F. Lauritzsen and Bjarne Bogen and has published in prestigious journals such as Journal of Clinical Investigation, Blood and Immunity.

In The Last Decade

Peter O. Hofgaard

19 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter O. Hofgaard Norway 13 741 500 269 149 65 19 1.0k
Orly Azogui France 15 1.2k 1.6× 383 0.8× 401 1.5× 118 0.8× 79 1.2× 25 1.5k
Kelly M. Ramsbottom Australia 16 654 0.9× 462 0.9× 414 1.5× 146 1.0× 20 0.3× 22 1.0k
Teresa Rasalan United States 12 953 1.3× 742 1.5× 293 1.1× 72 0.5× 63 1.0× 17 1.2k
Jürgen R. Müller United States 18 957 1.3× 415 0.8× 299 1.1× 152 1.0× 48 0.7× 30 1.3k
Christelle Harly United States 18 1.5k 2.0× 431 0.9× 305 1.1× 59 0.4× 48 0.7× 28 1.7k
Dirk M. van der Steen Netherlands 14 432 0.6× 440 0.9× 283 1.1× 109 0.7× 49 0.8× 28 747
Warren S. Alexander Australia 8 402 0.5× 205 0.4× 153 0.6× 76 0.5× 37 0.6× 8 681
Chainarong Tunyaplin United States 12 864 1.2× 267 0.5× 406 1.5× 74 0.5× 72 1.1× 12 1.3k
Juan J. Pérez‐Villar Spain 18 1.7k 2.3× 592 1.2× 315 1.2× 87 0.6× 74 1.1× 24 2.0k
Pascal Chaux France 14 1.3k 1.7× 544 1.1× 594 2.2× 96 0.6× 151 2.3× 22 1.5k

Countries citing papers authored by Peter O. Hofgaard

Since Specialization
Citations

This map shows the geographic impact of Peter O. Hofgaard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter O. Hofgaard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter O. Hofgaard more than expected).

Fields of papers citing papers by Peter O. Hofgaard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter O. Hofgaard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter O. Hofgaard. The network helps show where Peter O. Hofgaard may publish in the future.

Co-authorship network of co-authors of Peter O. Hofgaard

This figure shows the co-authorship network connecting the top 25 collaborators of Peter O. Hofgaard. A scholar is included among the top collaborators of Peter O. Hofgaard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter O. Hofgaard. Peter O. Hofgaard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Gaschet, Joëlle, Séverine Marionneau‐Lambot, Peter O. Hofgaard, et al.. (2023). Preclinical Evaluation of a 64Cu-Based Theranostic Approach in a Murine Model of Multiple Myeloma. Pharmaceutics. 15(7). 1817–1817. 6 indexed citations
2.
Westhrin, Marita, Ana Textor, Peter O. Hofgaard, et al.. (2023). Id-neoantigen vaccine induces therapeutic CD8+ T cells against multiple myeloma: H chain-loss escapees cause FLC MM. Journal for ImmunoTherapy of Cancer. 11(8). e006944–e006944. 1 indexed citations
3.
Fløisand, Yngvar, Simone Bürgler, Peter O. Hofgaard, et al.. (2017). Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice. Leukemia. 31(10). 2114–2121. 10 indexed citations
4.
Kikuchi, Jiro, Daisuke Koyama, Taeko Wada, et al.. (2015). Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma. Experimental Hematology. 43(9). S64–S64. 1 indexed citations
5.
Kikuchi, Jiro, Daisuke Koyama, Taeko Wada, et al.. (2015). Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma. Journal of Clinical Investigation. 125(12). 4375–4390. 82 indexed citations
6.
Haabeth, Ole Audun Werner, Anders Tveita, Marte Fauskanger, et al.. (2014). How Do CD4+ T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?. Frontiers in Immunology. 5. 174–174. 152 indexed citations
7.
Hofgaard, Peter O., Henriette C. Jodal, Kurt Bommert, et al.. (2012). A Novel Mouse Model for Multiple Myeloma (MOPC315.BM) That Allows Noninvasive Spatiotemporal Detection of Osteolytic Disease. PLoS ONE. 7(12). e51892–e51892. 55 indexed citations
8.
Hofgaard, Peter O., Harald Hauglin, Soheil Naderi, et al.. (2011). Cyclic AMP induces apoptosis in multiple myeloma cells and inhibits tumor development in a mouse myeloma model. BMC Cancer. 11(1). 301–301. 33 indexed citations
9.
Corthay, Alexandre, Katrin U. Lundin, Kristina Berg Lorvik, Peter O. Hofgaard, & Bjarne Bogen. (2009). Secretion of Tumor-Specific Antigen by Myeloma Cells Is Required for Cancer Immunosurveillance by CD4+ T Cells. Cancer Research. 69(14). 5901–5907. 41 indexed citations
10.
Hofgaard, Peter O., et al.. (2008). Depletion of CD4+ CD25+ regulatory T cells inhibits local tumour growth in a mouse model of B cell lymphoma. Clinical & Experimental Immunology. 152(2). 381–387. 17 indexed citations
11.
Corthay, Alexandre, Katrin U. Lundin, Egil Røsjø, et al.. (2005). Primary Antitumor Immune Response Mediated by CD4+ T Cells. Immunity. 22(3). 371–383. 346 indexed citations
12.
Dembić, Zlatko, Peter O. Hofgaard, Hilde Omholt, & Bjarne Bogen. (2004). Anti‐Class II Antibodies, but not Cytotoxic T‐Lymphocyte Antigen 4–Immunoglobulin Hybrid Molecules, Prevent Rejection of Major Histocompatibility Complex Class II‐Negative Myeloma in T‐Cell Receptor‐Transgenic Mice. Scandinavian Journal of Immunology. 60(1-2). 143–152. 3 indexed citations
13.
Lundin, Katrin U., Valentina Screpanti, Hilde Omholt, et al.. (2004). CD4+ T cells kill Id+ B-lymphoma cells: FasLigand-Fas interaction is dominant in vitro but is redundant in vivo. Cancer Immunology Immunotherapy. 53(12). 1135–1145. 22 indexed citations
14.
Lundin, Katrin U., Peter O. Hofgaard, Hilde Omholt, et al.. (2003). Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies. Blood. 102(2). 605–612. 35 indexed citations
15.
Dellacasagrande, Jérôme, Olav Schreurs, Peter O. Hofgaard, et al.. (2003). Liver Metastasis of Cancer Facilitated by Chemokine Receptor CCR6. Scandinavian Journal of Immunology. 57(6). 534–544. 60 indexed citations
16.
Lauritzsen, Grete F., Peter O. Hofgaard, Karl Schenck, & Bjarne Bogen. (1998). Clonal deletion of thymocytes as a tumor escape mechanism. International Journal of Cancer. 78(2). 216–222. 51 indexed citations
17.
Lauritzsen, Grete F., Peter O. Hofgaard, Karl Schenck, & Bjarne Bogen. (1998). Clonal deletion of thymocytes as a tumor escape mechanism. International Journal of Cancer. 78(2). 216–222. 3 indexed citations
18.
Bogen, Bjarne, Ludvig A. Munthe, Peter O. Hofgaard, et al.. (1995). Naive CD4+ T cells confer idiotype‐specific tumor resistance in the absence of antibodies. European Journal of Immunology. 25(11). 3079–3086. 71 indexed citations
19.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Orly Azogui Breakdown of academic impact, for papers by Kelly M. Ramsbottom Breakdown of academic impact, for papers by Teresa Rasalan Breakdown of academic impact, for papers by Jürgen R. Müller Breakdown of academic impact, for papers by Christelle Harly Breakdown of academic impact, for papers by Dirk M. van der Steen Breakdown of academic impact, for papers by Warren S. Alexander Breakdown of academic impact, for papers by Chainarong Tunyaplin Breakdown of academic impact, for papers by Juan J. Pérez‐Villar Breakdown of academic impact, for papers by Pascal Chaux
Rankless by CCL
2026